Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 3/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10205366 | 0.88 | HCAR2 (0.36) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL25152124 | 0.80 | HCAR2 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL23489973 | 0.79 | PSEN1 (0.34) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL26524370 | 0.79 | PSEN1 (0.34) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22758634 | 0.79 | NR1I2 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18948474 | 0.79 | NR1I2 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL15158969 | 0.76 | PSEN1 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL26897150 | 0.76 | HCAR2 (0.32) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL25152079 | 0.76 | HCAR2 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12049686 | 0.75 | HCAR2 (0.35) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2019-07-16 | — | — | US | disclosed |
| EP-2938344-B1 | PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME (US) | 2017-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | PSEN1 278/4885PSEN2 530/4885APH1B 1795/4885 |
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | PSEN1 2972/4885PSEN2 4255/4885APH1B 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.